Bristol Myers Squibb’s Cobenfy failed to outdistance a placebo in a Phase 3 test that evaluated the drug as an adjunct to antipsychotics in schizophrenia patients. Last September, the FDA approved Cobenfy as a standalone schizophrenia treatment. The post Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics appeared first on…
Dr Kimmie Ng discusses cancer with Dr. George Beauregard. Dr Ng heads the Young-Onset Colorectal Cancer Center, at the legendary Dana Farber Cancer Institute, and she treated George’s son who died age 32. Why are these cancers in younger people increasing so quickly? What can we do about it? What is connecting the environment, the…
With positive Phase 1 results for the metabolic disorder drug MZE782, Maze Therapeutics plans to advance the small molecule to Phase 2 tests in phenylketonuria and chronic kidney disease. Following the data readout, Maze raised $150 million in a private placement. The post Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for…
Lundbeck says Longboard Pharmaceuticals’ drug, bexicaserin, has potential applications in a range of rare epilepsies. Last month, the biotech began a Phase 3 clinical trial testing the drug in Dravet syndrome. The post Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition appeared first on MedCity News.
The Commonwealth Fund’s new report examines the facts—and implications—of underinsurance
Several states and insurers have gold carding programs to streamline prior authorization. However, some say they’re falling short. The post Gold Carding Programs Are Meant to Improve Prior Authorization. Are They Working? appeared first on MedCity News.
Over the past decade, Abbott and Dexcom — the two largest makers of continuous glucose monitors — have been teaming up with medical device companies that sell automated insulin delivery systems. Industry experts think these partnerships are smart moves to stay relevant in the rapidly-developing diabetes care space. The post The Surprising Rivalries-Turned-Friendships That Are…
This new standard was developed to address the rise of telehealth, cybersecurity risks/compliance in ePrescribing, data needs, AI, and the growing demand for patient transparency. So what is the Standard solving for, and what can providers expect? The post What Providers Need to Know About the Coming NCPDP Transition appeared first on MedCity News.
SIKESTON, Mo. — In the summer of 2021, Sikeston residents organized the biggest Juneteenth party in the city’s history. Sikeston police officers came too, both to provide security for the event and to try to build bridges with the community. But after decades of mistrust, some residents questioned their motives. In the series finale of…
A review of the 2025 Medicare Advantage plans available for individual enrollment shows that the total number of plans declined by 7% (from 3,959 to 3,699). The average Medicare beneficiary will have the option of 34 Medicare Advantage prescription drug (MA-PD) plans in 2025, just 2 fewer than the 36 options available in 2024. Since…